| ratiopharm GmbH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128773 | DESFESOTERODINE IN THE FORM OF A TARTARIC ACID SALT - The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form. | 05-24-2012 |
| 20120122973 | DRY PROCESSING OF RETIGABINE - The invention relates to dry processes for the production of oral dosage forms, especially tablets, containing retigabine and adhesion promoter. In addition, the invention relates to compacted intermediates containing retigabine and an adhesion promoter. Finally, the invention relates to single-dose and multiple-dose containers, preferably sachets and stick-packs, containing the intermediate of the invention. | 05-17-2012 |
| 20120071488 | MELTING TABLET CONTAINING A SILDENAFIL SALT - The invention relates to an orodispersible tablet comprising the components pharmaceutically acceptable sildenafil salt (a), polymeric adsorbent (b), in particular cation exchanger resin, sweetener (c), and flavoring (d) and, preferably, mucilage (e) and glidant (f). The invention furthermore relates to a process for the preparation of orodispersible tablets comprising a pharmaceutically acceptable sildenafil salt and to the use of a combination of cation exchanger resin and mucilage for masking the flavor of medicaments for treating erectile dysfunction | 03-22-2012 |
| 20120058183 | RETIGABINE TABLETS, PREFERABLY HAVING MODIFIED RELEASE - The invention relates to tablets, especially tablets with modified release, containing (a) retigabine and a combination of (b) water-soluble excipient and (c) non-water-soluble excipient; and a process for producing them. | 03-08-2012 |
| 20120022087 | AMORPHOUS AMBRISENTAN - The invention relates to amorphous ambrisentan, preferably together with a surface stabiliser in the form of a stable intermediate. The invention further relates to methods of producing stable amorphous ambrisentan and pharmaceutical formulations containing stable amorphous ambrisentan. | 01-26-2012 |
| 20120015965 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY] PHENYL]-6-[5[[[2-(METHYLSULFONYL) ETHYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition. | 01-19-2012 |
| 20120009258 | COMPACTED CINACALCET - The invention relates to an intermediate, obtainable by jointly compacting (i) crystalline cinacalcet or a pharmaceutically acceptable salt thereof, with (ii) a hydrophilising agent, and also tablets containing the intermediates of the invention. The invention further relates to cinacalcet tablets with a bimodal pore size distribution and a method of preparing the tablets of the invention. Finally, the invention relates to the use of a pH adjuster for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 01-12-2012 |
| 20110313050 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-22-2011 |
| 20110305762 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-6-[5[[[2-(METHYLSULFONYL)E- THYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition. | 12-15-2011 |
| 20110300214 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions. | 12-08-2011 |
| 20110295005 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES - The present invention relates to a process for preparing pyrimidine derivatives of the formula V, in particular as intermediates useful for preparing pyrimidine derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, such as HMG-CoA reductase inhibitors, e.g. rosuvastatin. | 12-01-2011 |
| 20110293717 | COMPACTED MOXIFLOXACIN - The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin. | 12-01-2011 |
| 20110281912 | ORAL DISPERSIBLE TABLET - The present invention relates to an oral dispersible tablet comprising at least one filler selected from sugars and sugar alcohols, and microcrystalline cellulose. | 11-17-2011 |
| 20110189279 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions with modified release properties comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and process of preparing such compositions. | 08-04-2011 |
| 20110189121 | BITABLETS COMPRISING COMPACTED POLYALLYLAMINE POLYMER AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to a method for producing tablets comprising a polyallylamine polymer, comprising the steps (i) preparation of a polyallylamine polymer or pharmaceutically compatible salts thereof, optionally in a mixture with one or more pharmaceutical excipients; (ii) compaction to give a slug; (iii) granulation of the slug; and (iv) compression of the resulting granules to give tablets; and also to tablets, sachets and slugs comprising a compacted polyallylamine polymer. In addition, the invention relates to tablets comprising a polyallylamine polymer, in particular Sevelamer, with a bimodal pore size distribution. | 08-04-2011 |
| 20110165235 | DIRECTLY PRESSED ALISKIREN TABLETS - The invention relates to pharmaceutical compositions which contain the active agent Aliskiren and are suitable for the production of tablets by dry pressing, so that prior wet granulation can be obviated. The invention also relates to tablets which can be obtained by dry pressing of these pharmaceutical compositions and to a method for producing these tablets. The invention furthermore relates to the use of the novel pharmaceutical compositions and tablets for treating hypertension and illnesses associated therewith. | 07-07-2011 |
| 20110065920 | PROCESS FOR PREPARING PENTANOIC DIACID DERIVATIVES - The present invention relates to a process for preparing pentanoic diacid derivatives useful for preparing pyrimidine derivatives, in particular as intermediates useful for preparing pyrimidine derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, such as HMG-CoA reductase inhibitors, e.g. rosuvastatin. | 03-17-2011 |
| 20110034703 | CRYSTAL FORMS OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE- NE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE AND METHODS FOR THEIR PREPARATION - The present invention relates to novel crystal forms of Sunitinib and methods for their preparation. | 02-10-2011 |
| 20110008428 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC - The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions. | 01-13-2011 |
| 20100323017 | Escitalopram and Solid Pharmaceutical Composition Comprising the Same - The present invention relates to Escitalopram having a small median particle size and a solid pharmaceutical composition comprising the same. | 12-23-2010 |
| 20100310668 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE- NE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE - The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient. | 12-09-2010 |
| 20100291207 | PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE - The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 μm to 35 μm and d(0.5) of 3 μm to 20 μm, as well as methods for preparing said formulations. | 11-18-2010 |
| 20100234636 | Novel Salts of the Active Substance Rasagiline - The invention relates to novel salts of the active substance rasagiline. The salts show excellent processability even after prolonged storage and an excellent storage stability usually superior to known salts after being processed into tablets. | 09-16-2010 |
| 20100217008 | PROCESS FOR THE PREPARATION OF VALSARTAN AND INTERMEDIATE PRODUCTS - The present invention relates to a new method for the production of valsartan, a valine derivative having the chemical N name is (S)—N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amine, and pharmacologically acceptable salts thereof. Furthermore the invention relates to new intermediate compounds which are suitable for the production of valsartan and new methods for the production of intermediate compounds which are suitable for the production of valsartan. | 08-26-2010 |
| 20100179159 | METHOD FOR THE PRODUCTION OF A MEDICAMENT CONTAINING TADALAFIL - The invention relates to a method for producing a medicament containing tadalafil. In said method, tadalafil is mixed with suitable adjuvants and is heated to a temperature of about 100° C. to about 200° C., preferably about 150° C. to about 200° C., especially about 200° C. | 07-15-2010 |
| 20100159003 | PROCESS FOR THE PREPARATION OF A MEDICAMENT COMPRISING VARDENAFIL HYDROCHLORIDE TRIHYDRATE - The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C. | 06-24-2010 |
| 20100151012 | STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE - Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline. | 06-17-2010 |
| 20100137447 | METHOD FOR THE PRODUCTION OF ADSORBATES OF A RASAGILINE SALT HAVING A WATER-SOLUBLE ADJUVANT - The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance. | 06-03-2010 |
| 20100104640 | PHARMACEUTICAL COMPOSITIONS COMPRISING IRBESARTAN - The present invention relates to a pharmaceutical composition comprising irbesartan. | 04-29-2010 |
| 20090220597 | RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose. | 09-03-2009 |
| 20090149677 | Stereoselective Method for the Production of (R)-Dimepranol - The present invention relates to processes for preparing a compound of the general formula (Ia) | 06-11-2009 |
| 20090111994 | Method for The Production of Losartan - The present invention relates to a novel process for preparing losartan, an imidazole derivative with the chemical name 2-n-butyl-4-chloro-5-hydroxymethyl-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-]methyl}imidazole, and pharmacologically active salts thereof. The invention further relates to novel intermediates which are suitable for preparing losartan and to novel processes for preparing intermediate compounds which are suitable for preparing losartan. | 04-30-2009 |
| 20080319195 | Enantioselective Preparation of Benzimidazole Derivatives and Their Salts - The invention relates to a new process for preparing benzimidazole derivatives having a chiral sulfoxide group in enantiomerically pure form or in a form in which one of the two enantiomers is present in an increased quantity over the other enantiomer. The invention likewise relates to a process for preparing the salts of the individual enantiomers of the benzimidazole derivatives with a chiral sulfoxide group. The invention relates in particular to a process for preparing the S-enantiomer of omeprazole (also known as esomeprazole) and the salts thereof, more particularly the zinc salt of the S-enantiomer of omeprazole. In the new process a prochiral sulfide is oxidized in an organic solvent with an oxidizing agent in the presence of a titanium(IV) complex. | 12-25-2008 |
